Anthrasil Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to government biodefense initiatives, clinical success of immune globulin therapy, lack of alternative toxin neutralizers, national emergency preparedness programs, regulatory emergency approvals.

The growth in the forecast period can be attributed to continued public health preparedness funding, expansion of biodefense stockpiles, rising focus on rapid toxin neutralization, improved plasma derived product processing, long term government purchasing agreements. Major trends in the forecast period include growing use of anthrax immune globulin therapies, expansion of combination treatment protocols, increased strategic stockpiling of immune globulins, rising focus on toxin neutralization therapies, enhanced pediatric and adult anthrax management.

The increasing prevalence of anthrax infections is expected to drive the growth of the Anthrasil market going forward. Anthrax is an infectious disease caused by the bacterium Bacillus anthracis and can be transmitted through skin contact, inhalation, or ingestion, leading to severe and potentially life-threatening symptoms depending on the route of exposure. The rise in anthrax cases is linked to greater exposure to infected animals, insufficient veterinary oversight, and socioeconomic challenges that limit effective disease prevention and control measures. As the incidence of anthrax increases, the need for effective treatments such as Anthrasil also rises, as it provides immediate passive immunity and helps improve survival outcomes in affected patients. For instance, in December 2023, according to a report published by the World Health Organization (WHO), suspected anthrax cases in Zambia increased from 42 between September 2022 and January 2023 to 684 by November 20, 2023, including four deaths (0.6% case fatality rate), across 44 districts in nine of the country’s ten provinces. Therefore, the growing prevalence of anthrax infections is driving the Anthrasil market.

Major companies operating in the Anthrasil market are emphasizing innovative vaccine development approaches, such as cell-free filtrate technology, to improve efficacy, enhance safety profiles, and address emerging bioterrorism threats. Cell-free filtrate technology utilizes non-living components derived from an avirulent strain of Bacillus anthracis, reducing the risk of adverse reactions while still effectively stimulating an immune response. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company specializing in vaccines and antibody therapeutics for infectious diseases, received U.S. Food and Drug Administration (FDA) approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted). This vaccine represents a notable advancement in anthrax prevention, incorporating the adjuvant CPG7909 to strengthen and accelerate antibody production against Bacillus anthracis. CYFENDUS is manufactured using cell-free filtrates from an avirulent strain of the bacterium, ensuring it contains no live or dead organisms and potentially lowering the risk of adverse reactions compared with traditional whole-cell vaccines.

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired a U.S. sterile manufacturing facility from Emergent BioSolutions for an undisclosed amount. This acquisition enables Bora Pharmaceuticals to expand its biotechnology and pharmaceutical manufacturing capabilities and strengthen its contract development and manufacturing organization (CDMO) portfolio. Emergent BioSolutions Inc. is a US-based company involved in the manufacturing of Anthrasil.

Major companies operating in the anthrasil market are Emergent BioSolutions Inc.

North America was the largest region in the Anthrasil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrasil market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anthrasil market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have had a moderate impact on the anthrasil market by increasing costs for plasma collection materials and biologic processing inputs. These effects are most visible in hospital pharmacy and government stockpile distribution channels. Higher tariffs can raise procurement costs for critical biodefense therapies. However, they also support investments in domestic plasma processing infrastructure. This improves long term supply resilience for anthrax treatments.

The anthrasil market research report is one of a series of new reports that provides anthrasil market statistics, including anthrasil industry global market size, regional shares, competitors with a anthrasil market share, detailed anthrasil market segments, market trends and opportunities, and any further data you may need to thrive in the anthrasil industry. This anthrasil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anthrasil is an anthrax immune globulin obtained from the plasma of individuals who have been immunized with the anthrax vaccine and is used alongside antibiotics for the treatment of inhalational anthrax in both adult and pediatric patients. It functions by neutralizing anthrax toxins, thereby preventing cellular injury and reducing the severity of infection.

The main types of Anthrasil include 60U and 100U formulations. The 60U category consists of Anthrasil products supplied in 60-unit doses and is intended for use in hospitals, clinics, and other healthcare facilities. The clinical indications include inhalational anthrax, anthrax toxin neutralization, severe or systemic anthrax infections, prevention of disease progression in at-risk populations, and post-exposure prophylaxis (PEP). The end users include hospital pharmacies, retail pharmacies, and other healthcare providers.

The anthrasil market consists of sales of anthrasil (anthrax immune globulin intravenous - AIGIV), and anthrax vaccine adsorbed (AVA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.